Literature DB >> 23134850

[Cytomegalovirus-specific T cells immune reconstitution after human leukocyte antigen matched sibling donor allogeneic bone marrow plus peripheral blood hematopoietic stem cell transplantation].

Xiao-hua Luo1, Ying-jun Chang, Ming-rui Huo, Dan Li, Xiao-jun Huang.   

Abstract

OBJECTIVE: To investigate the regular pattern of Cytomegalovirus (CMV)-specific T cells (CTL) immune reconstitution after human leukocyte antigen (HLA) matched sibling donor allogeneic bone marrow(BM) plus peripheral blood hematopoietic stem cell (PBSC) transplantation.
METHODS: CTL from seventeen patients after transplantation was detected by flow cytometry, the IFN-γ secretion ability of CTL by enzyme-linked immunospot (ELISPOT) assay, and clonal analysis of TCR Vβ subfamily by gene scan assays. The relationship between CTL reconstitution and CMV infection was studied.
RESULTS: Both number and function of recipients CTL reached to normal control level at 30 d post-transplantation. The recipients achieved a high frequency CTL with IFN-γ response and restoration of T-cell receptor β (TCR Vβ) repertoire at one year post-transplantation. CTL with the central memory CD45RO(+)CD62L(+) cell phenotype expanded in PB when CMV was reactivated. The incidence of CMV reactivation was 35.83% (17.91% - 63.10%) after transplantation, and none of them developed CMV disease.
CONCLUSION: After HLA matched related donor transplantation using mixed grafts, immune recovery to CMV seems to be early and fast. The incidence of CMV infection and disease are low.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23134850

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


  2 in total

1.  [Clinical features and prognosis of infection related to allogeneic hematopoietic stem cell transplantation in patients with blood diseases].

Authors:  M Guo; T Wu; H Bai; R Xi; C B Wang; Y Z Pan; Y G Cai; Q S Feng; M Lei
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-01-14

2.  Co-transplantation of mesenchymal stem cells makes haploidentical HSCT a potential comparable therapy with matched sibling donor HSCT for patients with severe aplastic anemia.

Authors:  Zenghui Liu; Xiaoxiong Wu; Shunqing Wang; Linghui Xia; Haowen Xiao; Yonghua Li; Hongbo Li; Yuping Zhang; Duorong Xu; Danian Nie; Yongrong Lai; Bingyi Wu; Dongjun Lin; Xin Du; Zujun Jiang; Yang Gao; Xuekui Gu; Yang Xiao
Journal:  Ther Adv Hematol       Date:  2020-10-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.